Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095053
Filing Date
2024-08-12
Accepted
2024-08-12 07:00:23
Documents
79
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q apge-20240630.htm   iXBRL 10-Q 2049852
2 EX-10.1 apge-ex10_1.htm EX-10.1 11415
3 EX-10.2 apge-ex10_2.htm EX-10.2 108503
4 EX-10.3 apge-ex10_3.htm EX-10.3 16340
5 EX-10.4 apge-ex10_4.htm EX-10.4 15843
6 EX-10.5 apge-ex10_5.htm EX-10.5 34173
7 EX-31.1 apge-ex31_1.htm EX-31.1 14814
8 EX-31.2 apge-ex31_2.htm EX-31.2 14841
9 EX-32.1 apge-ex32_1.htm EX-32.1 12274
  Complete submission text file 0000950170-24-095053.txt   8553307

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apge-20240630.xsd EX-101.SCH 1117136
82 EXTRACTED XBRL INSTANCE DOCUMENT apge-20240630_htm.xml XML 1406346
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41740 | Film No.: 241194690
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)